RxDoctor Payments Data

Steven Maurides

Cardiovascular Disease · Greenville, SCNPI 1447789482

Payments from drug & device makers

$2,298in general payments, 2019–2025

Across 109 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$412
  • Novartis$271
  • Philips North America LLC$264
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$231
  • E.r. Squibb & Sons, L.L.C.$183
  • Boehringer Ingelheim$128
  • plus $810 from 18 others

What the payments were for

  • Food & beverage$2,298100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,298 in reported general payments places this provider in the 35th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$200,731
Medicare patients
1,510
Services billed
3,095

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban396$348,732
JardianceEmpagliflozin94$113,245
EntrestoSacubitril/Valsartan78$91,312
XareltoRivaroxaban81$74,505
Repatha SureclickEvolocumab65$62,199
FarxigaDapagliflozin Propanediol31$37,622
Praluent PenAlirocumab18$14,522
Metoprolol Succinate467$5,398
VascepaIcosapent Ethyl14$5,247
Ezetimibe149$3,661
Icosapent Ethyl17$3,096
Rosuvastatin Calcium284$2,919
Atorvastatin Calcium230$2,110
Amiodarone Hcl35$1,221
Bumetanide11$977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$91$348,732396 claims
Boehringer IngelheimJardiance$128$113,24594 claims
NovartisEntresto$271$91,31278 claims
Johnson & JohnsonXarelto$54$74,50581 claims
AstraZenecaFarxiga$68$37,62231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →